Publications

Via Oncology Publications


 

Page R et al. Expanding indications of existing drugs and associated costs under risk reimbursement models.
[Abstract] J Clin Oncol 35, 2017 (suppl; abstr e18306)

 

Ellis PG et al. Using clinical pathways to understand biomarker testing patterns.
[Abstract] J Clin Oncol 35, 2017 (suppl; abstr e18189)

 

Ellis PG, O’Neil BH, Earle MF, et al. Clinical pathways: management of quality and cost in oncology networks in the metastatic colorectal cancer setting.
[Abstract] [Poster] J Oncol Pract. 2017 Apr 5.

 

Ellis PG et al. Developing and piloting an electronic telephone triage application.
[Abstract] [Poster] J Clin Oncol 35, 2017 (suppl 8S; abstract 137)

 

Lokay K, Ellis PG.Impact of single dose vial size availability on drug costs.
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl; abstr 6623)

 

Ellis PG et al. Impact of varying approaches used to compare costs between drug regimens.
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr e18262)

 

Friedland D et al. Evaluating the impact of Via Pathways (VP) on the adoption of changing treatment paradigms in metastatic hormone-sensitive prostate cancer (mHSPC).
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr e16510)

 

McCutcheon S et al. Frequency of efficacy, toxicity and cost as the deciding factor when determining clinical pathways
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr e18169)

 

Ellis PG et al. Pathways Clinical Decision Support for Appropriate Use of Key Biomarkers.
[Abstract] JOP May 24, 2016 JOPR010546

 

Clinical pathways as a platform to support clinical research
[Abstract] [Poster] Ellis PG, Weese JL. Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, 2016 (ABSTR 2594)

 

Ellis PG et al. Actionable biomarkers in a non-small cell lung cancer (NSCLC) clinical pathway (CP).
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 155)

 

Heron DE et al. The benefits of clinical pathways (CP) for radiation oncology in a large cancer care network.
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 148)

 

Heron DE et al. The standardization of skin cancer treatment recommendations through the analysis of clinical pathways data and an evidence-based, physician-driven committee process.
[Abstract] [Poster] J Clin Oncol 34, 2016 (suppl 7S; abstr 147)

 

Ellis PG et al. The usefulness of clinical pathways (CP) in managing quality and cost in oncology networks.
[Abstract] [Poster] J Clin Oncol 34 (suppl 4S; abstr 715) 2016

 

Ellis PG et al. Incorporation of a patient question prompt list into a pancreatic cancer pathway.
[Abstract] J Clin Oncol 33 (suppl 29S; abstr 20) 2015

 

Ellis PG, Lokay K. Clinical pathways and quality metrics.
[Abstract] J Clin Oncol 32 (suppl 30; abstr 273) 2014

 

Ellis PG, Lokay K. Pathways clinical decision support for appropriate use of key biomarker.
[Abstract] J Clin Oncol 32 (suppl 30; abstr 172) 2014

 

Lokay K, Heron DE. Reducing unwarranted variability in care in radiation oncology through clinical pathways.
[Abstract] J Clin Oncol 32 (suppl 30; abstr 171) 2014

 

Via Network Publications


 

Cost and survival analysis before and after implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer.
[Abstract] J Clin Oncol 35, 2017 (suppl 8S; abstract 3)

 

Gebhardt BJ et al. Peer review process for implementation of clinical pathways (CP): Does it improve compliance?
[Abstract] Pract Radiat Oncol. 2017 Jan 19. pii: S1879-8500(17)30006-1. doi: 10.1016/j.prro.2017.01.006.

 

Insights From Building a New National Cancer Institute Community Oncology Research Program Site
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr 6613)

 

Weese JL et al. Implementation of treatment pathways in a large integrated health care system.
[Abstract] J Clin Oncol 34, 2016 (suppl; abstr 6613)

 

Shamah CJ, Saphner TJ. Effect on clinical trial participation by integration of a clinical pathway program into an electronic health record (EHR).
[Abstract] J Clin Oncol 34, 2016 (suppl 7S; abstr 167)

 

Shamah CJ et al. Integration of a clinical pathways software into an EHR in a large, multisite, hospital-affiliated community oncology setting.
[Abstract] J Clin Oncol 34, 2016 (suppl 7S; abstr 129)

 

Gebhardt BJ et al. Impact of dynamic changes to a bone metastases pathway in a large, integrated, National Cancer Institute-designated comprehensive cancer center network.
[Abstract] Pract Radiat Oncol. 2015 Nov-Dec;5(6):398-405

 

Rajagopalan MS et al. Changing practice patterns for breast cancer radiation therapy with clinical pathways: An analysis of hypofractionation in a large, integrated cancer center network.
[Abstract] Pract Radiat Oncol. 2015 Mar-Apr;5(2):63-9

 

Newcomer LN et al. Changing physician incentives for affordable, quality cancer care: results of an episode payment model.
[Abstract] J Oncol Pract. 2014 Sep;10(5):322-6

 

Tan S et al. Development and implementation of clinical pathways in lung cancer at an academic comprehensive cancer center.
[Abstract] J Clin Oncol 32, 2014 (suppl 30; abstr 98)